Navigation Links
Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
Date:6/3/2008

LOS ANGELES, June 3 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has announced that it has appointed Mr. Lee B. Ehrlichman -- who is already a member of the company's Board of Directors -- as President and Chief Operating Officer. In that capacity, Mr. Ehrlichman's primary focus, in addition to monitoring and supervising company operations, will be on sales and marketing of the company's products.

Mr. Ehrlichman, who pioneered outpatient real-time cardiac telemetry technology and call center monitoring as Chief Executive Officer and President of Cardiac Telecom Corporation, will report directly to Signalife's Chief Executive Officer, Mr. Rowland Perkins. Mr. Ehrlichman's successful history is known and is public record, including for example his stint at Tartan, Inc., a company which he turned around after ten-years of losses, and later was sold to Texas Instruments.

Signalife also announced that it has moved its principal headquarters to Los Angeles -- where it was originally based -- in-house with the company's laboratory, R&D and IT operations, and close to the company's manufacturing operations in Ventura, California. Signalife has also expanded the square footage of its Los Angeles facilities in view of numerous additional staff members the company envisions it will add in the coming days in connection with its anticipated sales and marketing activities.

Dr. Lowell T. Harmison, Signalife's prior Chief Executive Officer and President, has taken an indefinite leave of absence as both an officer and director during which he is expected to consult to the company, as best he can, on a variety of matters.

In view of such leave, Mr. Rowland Perkins, previously Signalife's Interim Administrative Chief Executive Officer, will assume all duties of the office of Chief Executive Officer. Rowland Perkins, Signalife's Chief Executive Officer, commented: "I am personally excited and gratified to have somebody of Lee Ehrlichman's experience and talents now take command and control to expand on the many achievements of Dr. Harmison. On behalf of my colleagues, I am thankful to Dr. Harmison for all his hard work and efforts throughout the history of the company. I look forward to working with Dr. Harmison in his future advisory roles for Signalife."

Mr. Perkins said that he anticipates additional changes to the make-up of its Board of Directors, and other developments, later this week. An employment contract with Mr. Ehrlichman has been agreed to in principle and is expected to be executed over the next several days.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology procure market acceptance for these products, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the Signalife devices, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
2. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
3. Signalife Announces Webcast
4. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
5. Signalife Sees Accretive Purchase and Financial Commitments
6. Signalife Wins Second Frost & Sullivan Technology Award
7. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
8. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
9. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
10. U.S. Patent 7,299,083 Awarded to Signalife
11. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Switzerland from December 5-10. ... Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed ...
(Date:12/2/2016)... Conn. , Dec. 2, 2016  The Multiple ... presentations from the MMRF CoMMpass Study SM —the largest ... accelerating precision medicine in multiple myeloma—will be presented at ... Annual Meeting & Exposition in San Diego ... helping to optimize treatment strategies, as well as identify ...
(Date:12/2/2016)... 2, 2016 CytRx Corporation (NASDAQ: ... in oncology, today announced the appointment of Earl ... consultant, and private healthcare investor, to its Board of ... with clinical and strategic experience at the highest level," ... CEO. "As one of the world,s leading orthopedic surgeons, ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
Breaking Biology News(10 mins):